drugset / Trial / NCT03195023

Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

NCT03195023

RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (\>65 years old) patients with non-proteinuric nephropathies. Half of the patients will receive angiotensin converting enzyme inhibitors, while the other half will not receive them. Renal function, proteinuria and cardiovascular events will be follow up during a three year period.

Timeline

Start
2015-06
Primary completion
2019-12
Completion
2022-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Comparator LISINOPRIL ANHYDROUS Small molecule 20 mg